Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1413827

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1413827

Acute Care Syndromic Testing Market by Disease Type (Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases), Target (Bacteria, Fungi, Parasites), Sample Type, End User - Global Forecast 2024-2030

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & Online Access - 1 Year (Single User License)
USD 4749
PDF, Excel & Online Access - 1 Year (Up to 5 User License)
USD 5749
PDF, Excel & Online Access - 1 Year (Site License)
USD 6749
PDF, Excel & Online Access - 1 Year (Enterprise User License)
USD 8749

Add to Cart

[185 Pages Report] The Acute Care Syndromic Testing Market size was estimated at USD 3.40 billion in 2023 and expected to reach USD 3.74 billion in 2024, at a CAGR 9.99% to reach USD 6.63 billion by 2030.

Global Acute Care Syndromic Testing Market

KEY MARKET STATISTICS
Base Year [2023] USD 3.40 billion
Estimated Year [2024] USD 3.74 billion
Forecast Year [2030] USD 6.63 billion
CAGR (%) 9.99%
Acute Care Syndromic Testing Market - IMG1

Acute care syndromic testing refers to the rapid diagnostic process used in healthcare settings to identify the cause of a symptomatic patient's clinical symptoms by testing for multiple possible causes simultaneously. It facilitates qualitative detection and identification of viral, bacterial, fungal, and parasitic pathogens using real-time polymerase chain reaction (PCR). This approach is particularly significant in acute care settings where time-sensitive decisions are crucial, such as emergency departments or intensive care units. It employs panels of tests that cover a range of pathogens or conditions associated with a particular clinical syndrome, such as respiratory illness or gastrointestinal infection. The rise in infectious disease prevalence, including multi-drug-resistant pathogens, drives the need for rapid syndromic testing. Furthermore, government initiatives to improve medical infrastructure and stimulate the adoption of advanced diagnostics systems contribute to market growth. However, incidences of false positives and negatives and a lack of adequate reimbursements for certain syndromic tests can impede the adoption of acute care syndromic testing. Additionally, technical challenges and the ability to detect a limited number of microbial pathogens pose hurdles to the growth of the industry. However, key players are exploring the development of broader-ranging panels that can detect multiple pathogens in a single test. Research initiatives and advancements in clinical and medical microbiology can improve the performance and accuracy of acute care syndromic testing tools. Furthermore, the integration of advanced digital technologies such as AI/ML, data analysis technologies, and computational biology strategies can create new avenues of growth for the industry.

Regional Insights

The Americas region, particularly the US and Canada, boasts a robust healthcare infrastructure and digitalized healthcare framework, significantly driving the adoption of acute care syndromic testing in hospitals and clinics. Additionally, the Centers for Disease Control and Prevention (CDC) and other federal bodies actively encourage the development of rapid syndromic testing methods. Health insurers and hospitals are significant customers, and their purchasing behavior reflects a preference for integrated solutions that can provide quick results and aid in antimicrobial stewardship. The EU puts emphasis on compliance with stringent regulations pertaining to the healthcare sector. Additionally, strong collaborations between academic institutions, key players, and research institutes have led to innovations and improvements in the field of diagnostics and syndromic testing. Increasing antimicrobial resistance has also propelled the need for advanced diagnostics tools. In the APAC region, growing focus on healthcare reform and government initiatives and funds to expand access to advanced medical services and facilities are key factors leading to the adoption of acute care syndromic testing. Players in South Korea, India, and China are collaborating with diagnostic testing laboratories to expand the spread of acute care syndromic testing.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acute Care Syndromic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acute Care Syndromic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acute Care Syndromic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Applied BioCode, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, BIOHM Health LLC, bioMerieux SA, Curetis GmbH b y OpGen, Inc, CVS Health, Danaher Corporation, DiaSorin S.p.A, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Genetic Signatures Ltd., Hologic Inc., Luminex Corporation, Microbiologics, Inc., Pfizer, Inc., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.

Market Segmentation & Coverage

This research report categorizes the Acute Care Syndromic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Gastrointestinal Diseases
    • Genitourinary Diseases
    • Respiratory Diseases
    • Tropical Diseases
  • Target
    • Bacteria
    • Fungi
    • Parasites
    • Viruses
  • Sample Type
    • Biofluids
    • Blood
    • Stool
    • Swabs
    • Urine
  • End User
    • Clinical & Diagnostic Laboratories
    • Hospitals
    • Research & Academic Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Acute Care Syndromic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acute Care Syndromic Testing Market?

3. What are the technology trends and regulatory frameworks in the Acute Care Syndromic Testing Market?

4. What is the market share of the leading vendors in the Acute Care Syndromic Testing Market?

5. Which modes and strategic moves are suitable for entering the Acute Care Syndromic Testing Market?

Product Code: MRR-5A3042B3D696

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Acute Care Syndromic Testing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious disease outbreaks
      • 5.1.1.2. Utilization of syndromic tests for detecting antimicrobial resistance
      • 5.1.1.3. Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of false positives and false negatives and chances of contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Efforts to include syndromic testing under stewardship programs
      • 5.1.3.2. Advancements in clinical microbiology leading to improved testing strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations of acute care syndromic testing methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
    • 5.2.2. Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
    • 5.2.3. Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
    • 5.2.4. End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Acute Care Syndromic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Gastrointestinal Diseases
  • 6.3. Genitourinary Diseases
  • 6.4. Respiratory Diseases
  • 6.5. Tropical Diseases

7. Acute Care Syndromic Testing Market, by Target

  • 7.1. Introduction
  • 7.2. Bacteria
  • 7.3. Fungi
  • 7.4. Parasites
  • 7.5. Viruses

8. Acute Care Syndromic Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Biofluids
  • 8.3. Blood
  • 8.4. Stool
  • 8.5. Swabs
  • 8.6. Urine

9. Acute Care Syndromic Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Clinical & Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Research & Academic Institutions

10. Americas Acute Care Syndromic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Care Syndromic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Care Syndromic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player
    • 13.3.1. New Product Launch & Enhancement
      • 13.3.1.1. FDA Clears COVID-19 Home Antigen Test
      • 13.3.1.2. NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program
    • 13.3.2. Award, Recognition, & Expansion
      • 13.3.2.1. Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Applied BioCode, Inc.
    • 14.1.3. Becton, Dickinson and Company
    • 14.1.4. Bio-Rad Laboratories, Inc.
    • 14.1.5. Biocartis NV
    • 14.1.6. BIOHM Health LLC
    • 14.1.7. bioMerieux SA
    • 14.1.8. Curetis GmbH b y OpGen, Inc
    • 14.1.9. CVS Health
    • 14.1.10. Danaher Corporation
    • 14.1.11. DiaSorin S.p.A
    • 14.1.12. Eurofins Scientific SE
    • 14.1.13. F. Hoffmann-La Roche Ltd
    • 14.1.14. Genetic Signatures Ltd.
    • 14.1.15. Hologic Inc.
    • 14.1.16. Luminex Corporation
    • 14.1.17. Microbiologics, Inc.
    • 14.1.18. Pfizer, Inc.
    • 14.1.19. QIAGEN N.V.
    • 14.1.20. QuantuMDx Group Ltd.
    • 14.1.21. Seegene Inc.
    • 14.1.22. Siemens Healthineers AG
    • 14.1.23. Sysmex Corporation
    • 14.1.24. Thermo Fisher Scientific Inc.
    • 14.1.25. Werfen
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing
Product Code: MRR-5A3042B3D696

LIST OF FIGURES

  • FIGURE 1. ACUTE CARE SYNDROMIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACUTE CARE SYNDROMIC TESTING MARKET DYNAMICS
  • FIGURE 7. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2030 (%)
  • FIGURE 10. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ACUTE CARE SYNDROMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GENITOURINARY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 11. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRUSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BIOFLUIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STOOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 194. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ACUTE CARE SYNDROMIC TESTING MARKET LICENSE & PRICING
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!